ASCO 2024 Round Up: Advancements in Biomarker-Driven Medicines, Cancer Vaccines, and AI Applications Paving the Way for Expansion of Precision Oncology
Frost & Sullivan
JUNE 24, 2024
Merck and Moderna officially disclosed the three-year results from a phase IIb study of their collaborative cancer vaccine for resected melanoma in ASCO. Another ADC that gained significant attention was Enhertu, a collaboration between the AstraZeneca and the Daiichi Sankyo.
52 
Let's personalize your content